Health Care Week in Review May 3, 2019

Alston & Bird Healthcare Week in Review, May 3, 2019

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health policy news.

I. Regulations, Notices, & Guidance

  • On May 2, 2019, the Food and Drug Administration (FDA) issued a notice entitled, List of Patient Preference-Sensitive Priorities. As part of FDA’s commitments for the reauthorization of the Medical Device User Fee Amendments of 2017 (MDUFA IV), the Center for Devices and Radiological Health (CDRH) committed to publish a list of priority areas where preference-sensitive data can inform regulatory decision making. FDA is also establishing a docket to solicit public input on this list of preference-sensitive areas that may impact the design and conduct of premarket medical device clinical studies, benefit-risk assessments, and postmarket evaluation.
  • On May 2, 2019, the Centers for Medicare & Medicaid Services (CMS) issued a final rule entitled, Reassignment of Medicaid Provider Claims. This final rule removes the regulatory text that allows a state to make Medicaid payments to third parties on behalf of an individual provider for benefits such as health insurance, skills training, and other benefits customary for employees. CMS has concluded that this provision is neither explicitly nor implicitly authorized by the statute, which identifies the only permissible exceptions to the rule that only a provider may receive Medicaid payments. As CMS noted in their prior rulemaking, section 1902(a)(32) of the Social Security Act (the Act) provides for a number of exceptions to the direct payment requirement, but it does not authorize the CMS to create new exceptions.
  • On May 3, 2019, the FDA issued guidance entitled, Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment. The purpose of this draft guidance is to assist sponsors in the clinical development of stimulant drugs for treatment of attention deficit hyperactivity disorder in pediatric and adult patients. Specifically, the draft guidance addresses the FDA’s current recommendations regarding the development programs for methylphenidate and amphetamine products, as well as for novel products (i.e., new molecular entity stimulant drugs).
  • On May 3, 2019, CMS issued a final rule entitled, Changes to the Medicare Claims and Medicare Prescription Drug Coverage Determination Appeals Procedures. This final rule revises the regulations setting forth the appeals process that Medicare beneficiaries, providers, and suppliers must follow in order to appeal adverse determinations regarding claims for benefits under Medicare Part A and Part B or determinations for prescription drug coverage under Part D. These changes help to streamline the appeals process and reduce administrative burden on providers, suppliers, beneficiaries, and appeal adjudicators. These revisions, which include technical corrections, also help to ensure the regulations are clearly arranged and written to give stakeholders a better understanding of the appeals process.

Event Notices   

  • May 9 – 10, 2019: The FDA announced a meeting of the Pain Management Best Practices Inter-Agency Task Force. The Task Force will review clinical guidelines and identify gaps and/or inconsistencies for best practices for pain management.
  • May 13, 2019: The FDA announced a public meeting entitled, The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products. The hearing is set to discuss access to affordable insulin products and issues related to the development and approval of biosimilar and interchangeable insulin products.
  • June 11, 2019: The FDA announced a public meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. The Committee will discuss clinical utility and safety concerns associated with the higher range of opioid analgesic dosing in the outpatient setting.

II. Congressional Legislation & Committee Action

U.S. Senate

  • There were no health-related hearings this week.

House of Representatives

III. Reports, Studies, & Analyses

IV. Other Health Policy News

  • On May 2, 2019, the Congressional Budget Office (CBO) released its updated budget projections for 2019-2029. Along with the projections, CBO issued a supplemental document entitled, Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBOS’s Budget Projections. CBO estimates that implementing the Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees proposed rule would increase federal spending by about $177 billion over the 2020–2029 period with Medicare spending increasing by about $170 billion and Medicaid spending increasing by about $7 billion.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.